Lewis and Clark Pharmaceuticals Raises $100K in Funding

Lewis and Clark Pharmaceuticals, Inc., a Charlottesville, Va.-based developer of novel adenosine-based pharmaceutical compounds for autoimmune and other diseases, has raised $100k in funding.

The investment was made by the Center for Innovative Technology (CIT), via the GAP Funds.

The company intends to use to the capital to continue to advance its compounds.

Led by Robert Thompson, Ph.D., Founder and CEO, Lewis and Clark will initially focus its efforts on two large markets: stress imaging and autoimmune diseases such as rheumatoid arthritis.



Join the discussion